GCA
TXMD icon

Greenwood Capital Associates’s TherapeuticsMD TXMD Stock Holding History

Greenwood Capital Associates’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-728
Closed -$45K – 209
2020
Q2 		$45K Hold
728
– – 0.01% 183
2020
Q1 		$39K Sell
728
-8,985
-93% -$891K 0.01% 152
2019
Q4 		$1.18M Buy
9,713
+696
+8% +$100K 0.25% 77
2019
Q3 		$1.64M Sell
9,017
-1,343
-13% -$189K 0.4% 65
2019
Q2 		$1.35M Buy
10,360
+4,783
+86% +$857K 0.34% 65
2019
Q1 		$1.36M Buy
5,577
+119
+2% +$31.5K 0.35% 63
2018
Q4 		$1.04M Buy
5,458
+2,178
+66% +$531K 0.27% 69
2018
Q3 		$1.08M Buy
3,280
+1,547
+89% +$474K 0.23% 74
2018
Q2 		$541K Buy
1,733
+177
+11% +$54.1K 0.12% 92
2018
Q1 		$379K Buy
1,556
+71
+5% +$19.9K 0.09% 122
2017
Q4 		$449K Buy
1,485
+306
+26% +$85.2K 0.1% 121
2017
Q3 		$312K Buy
1,179
+69
+6% +$19.9K 0.08% 144
2017
Q2 		$292K Buy
1,110
+704
+173% +$176K 0.08% 148
2017
Q1 		$146K Buy
406
+60
+17% +$18.6K 0.04% 204
2016
Q4 		$100K Buy
+346
New +$107K 0.03% 185

Other funds holding TXMD

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return

Greenwood Capital Associates's TXMD Position: Q3 2020 in Review

Greenwood Capital Associates sold out of TherapeuticsMD (TXMD) in Q3 2020, closing a stake of 728 shares — an estimated $45K sold.

Greenwood Capital Associates first reported a position in TXMD in Q4 2016 and held it in 15 quarters. The position peaked at $1.64M in Q3 2019. 142 funds tracked by Wall St. Rank hold TXMD as of Q3 2020.

  • Greenwood Capital Associates reported no remaining TherapeuticsMD position as of Q3 2020 after selling out during the quarter.
  • Greenwood Capital Associates sold 728 TherapeuticsMD shares in Q3 2020, an estimated $45K.
  • Greenwood Capital Associates first reported a position in TherapeuticsMD in Q4 2016 and held it in 15 quarters.
  • Greenwood Capital Associates's TherapeuticsMD position peaked at $1.64M in Q3 2019.
  • 142 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2020.

Based on Greenwood Capital Associates's 13F filing for Q3 2020, filed 12 Nov 2020.